

Dafna D Gladman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6737587/publications.pdf>

Version: 2024-02-01

599
papers

57,920
citations

1799

103
h-index

1385

222
g-index

702
all docs

702
docs citations

702
times ranked

28662
citing authors

#	ARTICLE	IF	CITATIONS
1	Derivation of the sledai. A disease activity index for lupus patients. <i>Arthritis and Rheumatism</i> , 1992, 35, 630-640.	6.7	4,086
2	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 2677-2686.	6.7	3,838
3	Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. <i>Arthritis and Rheumatism</i> , 2006, 54, 2665-2673.	6.7	2,811
4	The development and initial validation of the systemic lupus international collaborating clinics/American college of rheumatology damage index for systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996, 39, 363-369.	6.7	2,042
5	Systemic lupus erythematosus disease activity index 2000. <i>Journal of Rheumatology</i> , 2002, 29, 288-91.	2.0	1,911
6	Genome-wide scan reveals association of psoriasis with IL-23 and NF- κ B pathways. <i>Nature Genetics</i> , 2009, 41, 199-204.	21.4	1,229
7	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	5.6	1,098
8	Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017, 376, 957-970.	27.0	931
9	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. <i>Nature Genetics</i> , 2012, 44, 1341-1348.	21.4	848
10	Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2005, 52, 3279-3289.	6.7	828
11	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. <i>Nature Genetics</i> , 2011, 43, 761-767.	21.4	778
12	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
13	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1060-1071.	5.6	726
14	Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related loci. <i>Nature Genetics</i> , 2013, 45, 730-738.	21.4	699
15	The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index in patients with Systemic Lupus Erythematosus. <i>Arthritis and Rheumatism</i> , 1997, 40, 809-813.	6.7	586
16	Psoriasis. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16082.	30.5	585
17	Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: Results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). <i>Arthritis and Rheumatism</i> , 2005, 52, 1227-1236.	6.7	583
18	Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2009, 60, 976-986.	6.7	547

#	ARTICLE	IF	CITATIONS
19	Epidemiology of psoriatic arthritis in the population of the United States. <i>Journal of the American Academy of Dermatology</i> , 2005, 53, 573.e1-573.e13.	1.2	499
20	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 3-17.	0.9	484
21	Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naïve patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 79-87.	0.9	454
22	Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2008, 58, 556-562.	6.7	447
23	Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors. <i>New England Journal of Medicine</i> , 2017, 377, 1525-1536.	27.0	405
24	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 729-735.	1.2	397
25	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1706-1713.	0.9	391
26	National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening. <i>Journal of the American Academy of Dermatology</i> , 2008, 58, 1031-1042.	1.2	383
27	Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1020-1026.	0.9	372
28	The frequency and outcome of lupus nephritis: results from an international inception cohort study. <i>Rheumatology</i> , 2016, 55, 252-262.	1.9	370
29	Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: A multinational, double-blind, randomized, placebo-controlled clinical trial. <i>Arthritis and Rheumatism</i> , 2004, 50, 1939-1950.	6.7	366
30	Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 251-265.e19.	1.2	362
31	Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2. <i>Nature Genetics</i> , 2010, 42, 991-995.	21.4	331
32	Mortality studies in psoriatic arthritis. Results from a single outpatient clinic. I. Causes and risk of death. <i>Arthritis and Rheumatism</i> , 1997, 40, 1868-1872.	6.7	315
33	Transancestral mapping and genetic load in systemic lupus erythematosus. <i>Nature Communications</i> , 2017, 8, 16021.	12.8	314
34	Cutting Edge: Susceptibility to Psoriatic Arthritis: Influence of Activating Killer Ig-Like Receptor Genes in the Absence of Specific HLA-C Alleles. <i>Journal of Immunology</i> , 2002, 169, 2818-2822.	0.8	313
35	Genome-wide association analysis identifies three psoriasis susceptibility loci. <i>Nature Genetics</i> , 2010, 42, 1000-1004.	21.4	313
36	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2019, 71, 5-32.	5.6	312

#	ARTICLE	IF	CITATIONS
37	Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2001, 45, 151-158.	6.7	302
38	Mortality studies in psoriatic arthritis: Results from a single outpatient center. II. Prognostic indicators for death. <i>Arthritis and Rheumatism</i> , 1998, 41, 1103-1110.	6.7	283
39	Changing Patterns in Mortality and Disease Outcomes for Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2008, 35, 2152-2158.	2.0	274
40	Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. <i>Arthritis and Rheumatism</i> , 2007, 56, 476-488.	6.7	266
41	Abatacept in the treatment of patients with psoriatic arthritis: Results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trial. <i>Arthritis and Rheumatism</i> , 2011, 63, 939-948.	6.7	264
42	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2019, 71, 2-29.	3.4	264
43	Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. <i>Nature Communications</i> , 2017, 8, 15382.	12.8	251
44	Cancer risk in systemic lupus: An updated international multi-centre cohort study. <i>Journal of Autoimmunity</i> , 2013, 42, 130-135.	6.5	249
45	Cutting Edge: Heterozygote Advantage in Autoimmune Disease: Hierarchy of Protection/Susceptibility Conferred by HLA and Killer Ig-Like Receptor Combinations in Psoriatic Arthritis. <i>Journal of Immunology</i> , 2004, 173, 4273-4276.	0.8	247
46	The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2010, 62, 863-868.	6.7	245
47	Genome-wide Association Analysis of Psoriatic Arthritis and Cutaneous Psoriasis Reveals Differences in Their Genetic Architecture. <i>American Journal of Human Genetics</i> , 2015, 97, 816-836.	6.2	245
48	The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 986-991.	0.9	240
49	Lupus and pregnancy studies. <i>Arthritis and Rheumatism</i> , 1993, 36, 1392-1397.	6.7	231
50	Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1. <i>Nature Communications</i> , 2015, 6, 7146.	12.8	220
51	Accrual of organ damage over time in patients with systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2003, 30, 1955-9.	2.0	218
52	Cardiovascular and other comorbidities in patients with psoriatic arthritis: A comparison with patients with psoriasis. <i>Arthritis Care and Research</i> , 2011, 63, 1729-1735.	3.4	214
53	Malignancy in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1996, 39, 1050-1054.	6.7	204
54	Lupus retinopathy. <i>Arthritis and Rheumatism</i> , 1988, 31, 1105-1110.	6.7	203

#	ARTICLE	IF	CITATIONS
55	The Incidence and Risk Factors for Psoriatic Arthritis in Patients With Psoriasis: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2016, 68, 915-923.	5.6	197
56	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.9	194
57	Depression and Anxiety in Psoriatic Disease: Prevalence and Associated Factors. <i>Journal of Rheumatology</i> , 2014, 41, 887-896.	2.0	184
58	Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1550-1558.	0.9	184
59	Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2152-2154.	0.9	183
60	Fine Mapping Major Histocompatibility Complex Associations in Psoriasis and Its Clinical Subtypes. <i>American Journal of Human Genetics</i> , 2014, 95, 162-172.	6.2	182
61	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. <i>Nature Reviews Rheumatology</i> , 2022, 18, 465-479.	8.0	182
62	Assessment of patients with psoriatic arthritis: A review of currently available measures. <i>Arthritis and Rheumatism</i> , 2004, 50, 24-35.	6.7	171
63	Golimumab in psoriatic arthritis: One-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2012, 64, 2504-2517.	6.7	171
64	Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone. <i>Rheumatology</i> , 2012, 51, 571-576.	1.9	166
65	Widespread non-additive and interaction effects within HLA loci modulate the risk of autoimmune diseases. <i>Nature Genetics</i> , 2015, 47, 1085-1090.	21.4	164
66	Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial. <i>Arthritis and Rheumatology</i> , 2019, 71, 1112-1124.	5.6	164
67	Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. <i>Lancet</i> , 2018, 392, 2367-2377.	13.7	159
68	Vitamin D insufficiency in a large female SLE cohort. <i>Lupus</i> , 2010, 19, 13-19.	1.6	157
69	Enhanced meta-analysis and replication studies identify five new psoriasis susceptibility loci. <i>Nature Communications</i> , 2015, 6, 7001.	12.8	156
70	Consensus on a core set of domains for psoriatic arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1167-70.	2.0	155
71	PREMATURE ATHEROSCLEROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Rheumatic Disease Clinics of North America</i> , 2000, 26, 257-278.	1.9	154
72	Functional Assessment of Chronic Illness Therapy-Fatigue Scale is valid in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 936-939.	0.9	153

#	ARTICLE	IF	CITATIONS
73	Association of interleukin-23 receptor variants with ankylosing spondylitis. <i>Arthritis and Rheumatism</i> , 2008, 58, 1020-1025.	6.7	152
74	Serologically active clinically quiescent systemic lupus erythematosus. <i>American Journal of Medicine</i> , 1979, 66, 210-215.	1.5	151
75	CARD15: a Pleiotropic Autoimmune Gene That Confers Susceptibility to Psoriatic Arthritis. <i>American Journal of Human Genetics</i> , 2003, 73, 677-681.	6.2	149
76	Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. <i>Nature Reviews Rheumatology</i> , 2018, 14, 363-371.	8.0	149
77	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1502-1509.	0.9	143
78	Soluble biomarkers differentiate patients with psoriatic arthritis from those with psoriasis without arthritis. <i>Rheumatology</i> , 2010, 49, 1399-1405.	1.9	142
79	Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: Results of a randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2006, 54, 1638-1645.	6.7	141
80	Obesity is associated with a lower probability of achieving sustained minimal disease activity state among patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 813-817.	0.9	138
81	Psoriasis in patients with HIV infection: From the Medical Board of the National Psoriasis Foundation. <i>Journal of the American Academy of Dermatology</i> , 2010, 62, 291-299.	1.2	132
82	Predictors for radiological damage in psoriatic arthritis: results from a single centre. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 370-376.	0.9	131
83	Human leucocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 50-55.	0.9	131
84	Sensitivity of the classification of psoriatic arthritis criteria in early psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2007, 57, 1560-1563.	6.7	129
85	Quality of life over time in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2008, 59, 181-185.	6.7	123
86	Longterm (52-week) Results of a Phase III Randomized, Controlled Trial of Apremilast in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 479-488.	2.0	122
87	Differences in body mass index among individuals with PsA, psoriasis, RA and the general population. <i>Rheumatology</i> , 2012, 51, 552-556.	1.9	120
88	Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 61, 1152-1158.	6.7	117
89	Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. <i>Rheumatology</i> , 2011, 50, 25-31.	1.9	115
90	Lymphoma risk in systemic lupus: effects of disease activity versus treatment. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 138-142.	0.9	115

#	ARTICLE	IF	CITATIONS
91	Summarizing disease features over time: I. Adjusted mean SLEDAI derivation and application to an index of disease activity in lupus. <i>Journal of Rheumatology</i> , 2003, 30, 1977-82.	2.0	115
92	The effect of pregnancy on lupus nephritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 3941-3946.	6.7	114
93	Association between the interleukin-1 family gene cluster and psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 2321-2325.	6.7	114
94	The Effect of Lupus Nephritis on Pregnancy Outcome and Fetal and Maternal Complications. <i>Journal of Rheumatology</i> , 2010, 37, 754-758.	2.0	114
95	Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome. <i>Journal of Rheumatology</i> , 2010, 37, 1822-1827.	2.0	114
96	The role of hla antigens as indicators of disease progression in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 845-850.	6.7	112
97	Association between environmental factors and onset of psoriatic arthritis in patients with psoriasis. <i>Arthritis Care and Research</i> , 2011, 63, 1091-1097.	3.4	112
98	Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1689-1694.	0.9	112
99	Treatment guidelines in psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, i37-i46.	1.9	111
100	Axial disease in psoriatic arthritis. <i>Current Rheumatology Reports</i> , 2007, 9, 455-460.	4.7	110
101	Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. <i>Arthritis Care and Research</i> , 2010, 62, 970-976.	3.4	110
102	Natural history of psoriatic arthritis. <i>Bailliere's Clinical Rheumatology</i> , 1994, 8, 379-394.	1.0	109
103	Improved survival in psoriatic arthritis with calendar time. <i>Arthritis and Rheumatism</i> , 2007, 56, 2708-2714.	6.7	109
104	Clinical Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort: Incidence, Prevalence, Characteristics, and Outcome. <i>Arthritis Care and Research</i> , 2017, 69, 1685-1691.	3.4	108
105	Psoriatic arthritis. <i>Dermatologic Therapy</i> , 2009, 22, 40-55.	1.7	106
106	PSORIATIC ARTHRITIS. <i>Rheumatic Disease Clinics of North America</i> , 1998, 24, 829-844.	1.9	105
107	The Early Protective Effect of Hydroxychloroquine on the Risk of Cumulative Damage in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2013, 40, 831-841.	2.0	105
108	Psoriatic arthritis. <i>F1000Research</i> , 2019, 8, 1665.	1.6	105

#	ARTICLE	IF	CITATIONS
109	International multicenter psoriasis and psoriatic arthritis reliability trial for the assessment of skin, joints, nails, and dactylitis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1235-1242.	6.7	104
110	Adjusted mean Systemic Lupus Erythematosus Disease Activity Index-2K is a predictor of outcome in SLE. <i>Journal of Rheumatology</i> , 2005, 32, 824-7.	2.0	103
111	Mycophenolate Mofetil for Induction Treatment of Lupus Nephritis: A Systematic Review and Metaanalysis. <i>Journal of Rheumatology</i> , 2011, 38, 69-78.	2.0	102
112	Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52-week Results from a Phase III Study (SPIRIT-P1). <i>Journal of Rheumatology</i> , 2018, 45, 367-377.	2.0	102
113	Patient Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA and OMERACT Study. <i>Journal of Rheumatology</i> , 2011, 38, 898-903.	2.0	101
114	Genome-Wide Meta-Analysis of Psoriatic Arthritis Identifies Susceptibility Locus at REL. <i>Journal of Investigative Dermatology</i> , 2012, 132, 1133-1140.	0.7	99
115	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2015, 67, 1837-1847.	5.6	98
116	Investigating the genetic basis for ankylosing spondylitis. Linkage studies with the major histocompatibility complex region. <i>Arthritis and Rheumatism</i> , 1994, 37, 1212-1220.	6.7	97
117	Atherosclerotic vascular events in a single large lupus cohort: prevalence and risk factors. <i>Journal of Rheumatology</i> , 2007, 34, 70-5.	2.0	97
118	Serum adipokines in patients with psoriatic arthritis and psoriasis alone and their correlation with disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1956-1961.	0.9	96
119	Genetic signature to provide robust risk assessment of psoriatic arthritis development in psoriasis patients. <i>Nature Communications</i> , 2018, 9, 4178.	12.8	95
120	Immunogenetic profile of patients with psoriatic arthritis varies according to the age at onset of psoriasis. <i>Arthritis and Rheumatism</i> , 1999, 42, 818-823.	6.7	94
121	Risk Factors for Axial Inflammatory Arthritis in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 809-815.	2.0	94
122	Clinical Features and Diagnostic Considerations in Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 569-579.	1.9	94
123	Axial Psoriatic Arthritis: Update on a Longterm Prospective Study. <i>Journal of Rheumatology</i> , 2009, 36, 2744-2750.	2.0	93
124	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	2.0	93
125	The Development of Psoriatic Arthritis in Patients With Psoriasis Is Preceded by a Period of Nonspecific Musculoskeletal Symptoms: A Prospective Cohort Study. <i>Arthritis and Rheumatology</i> , 2017, 69, 622-629.	5.6	93
126	Prolonged Clinical Remission in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2014, 41, 1808-1816.	2.0	90

#	ARTICLE	IF	CITATIONS
127	Description and prediction of physical functional disability in psoriatic arthritis: A longitudinal analysis using a Markov model approach. <i>Arthritis and Rheumatism</i> , 2005, 53, 404-409.	6.7	89
128	Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 578-582.	0.9	88
129	Is axial psoriatic arthritis distinct from ankylosing spondylitis with and without concomitant psoriasis?. <i>Rheumatology</i> , 2020, 59, 1340-1346.	1.9	88
130	Prolonged remission in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2005, 32, 1467-72.	2.0	87
131	<i>ERAP2</i> is associated with ankylosing spondylitis in <i>HLA-B27</i> -positive and <i>HLA-B27</i> -negative patients. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1627-1629.	0.9	86
132	Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. <i>Arthritis Research and Therapy</i> , 2010, 12, R113.	3.5	85
133	Incidence and predictors for cardiovascular events in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1680-1686.	0.9	85
134	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. <i>Arthritis and Rheumatism</i> , 2013, 65, 2887-2897.	6.7	84
135	The Framingham Risk Score underestimates the extent of subclinical atherosclerosis in patients with psoriatic disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1990-1996.	0.9	83
136	A longitudinal study of the effect of disease activity and clinical damage on physical function over the course of psoriatic arthritis: Does the effect change over time?. <i>Arthritis and Rheumatism</i> , 2007, 56, 840-849.	6.7	82
137	Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments. <i>Lupus Science and Medicine</i> , 2017, 4, e000239.	2.7	82
138	Incidence of arthritis in a prospective cohort of psoriasis patients. <i>Arthritis Care and Research</i> , 2011, 63, 619-622.	3.4	81
139	All-cause, cause-specific and age-specific standardised mortality ratios of patients with systemic lupus erythematosus in Ontario, Canada over 43 years (1971-2013). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 802-806.	0.9	80
140	The rate and pattern of organ damage in late onset systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2002, 29, 913-7.	2.0	80
141	HLA-C locus alleles in patients with psoriatic arthritis (PsA). <i>Human Immunology</i> , 1999, 60, 259-261.	2.4	79
142	Time to Recovery from Proteinuria in Patients with Lupus Nephritis Receiving Standard Treatment. <i>Journal of Rheumatology</i> , 2014, 41, 688-697.	2.0	79
143	Dyslipidemia in systemic lupus erythematosus: just another comorbidity?. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 45, 604-610.	3.4	79
144	Genetics of psoriasis and psoriatic arthritis: update and future direction. <i>Journal of Rheumatology</i> , 2008, 35, 1449-53.	2.0	79

#	ARTICLE	IF	CITATIONS
145	Excessive paternal transmission in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1228-1231.	6.7	78
146	SLEDAI-2K 10 days versus SLEDAI-2K 30 days in a longitudinal evaluation. <i>Lupus</i> , 2011, 20, 67-70.	1.6	78
147	Incremental Effects of Comorbidity on Quality of Life in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1349-1356.	2.0	78
148	Prevalence of malignancy in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 82-87.	6.7	77
149	Clinical efficacy, radiographic and safety findings through 2â€¦years of golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of the randomised, placebo-controlled GO-REVEAL study. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 1777-1785.	0.9	77
150	A comparison of five health status instruments in patients with systemic lupus erythematosus (SLE). <i>Lupus</i> , 1996, 5, 190-195.	1.6	76
151	Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. <i>Arthritis Care and Research</i> , 2012, 64, 511-518.	3.4	75
152	Is the Madrid Sonographic Enthesitis Index Useful for Differentiating Psoriatic Arthritis from Psoriasis Alone and Healthy Controls?. <i>Journal of Rheumatology</i> , 2014, 41, 466-472.	2.0	75
153	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. <i>Journal of Rheumatology</i> , 2007, 34, 1740-5.	2.0	74
154	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1759-1766.	3.4	73
155	Psoriatic Arthritis. <i>New England Journal of Medicine</i> , 2017, 376, 2094-2096.	27.0	73
156	Association of Interleukin 23 Receptor Variants with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2009, 36, 137-140.	2.0	72
157	Development and Initial Validation of the Systemic Lupus Erythematosus Disease Activity Index 2000 Responder Index 50. <i>Journal of Rheumatology</i> , 2011, 38, 275-284.	2.0	72
158	Dactylitis in Psoriatic Arthritis: Prevalence and Response to Therapy in the Biologic Era. <i>Journal of Rheumatology</i> , 2013, 40, 1357-1359.	2.0	72
159	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 345-355.	5.6	72
160	Psoriatic arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 1511-1522.	4.1	71
161	Importance of cumulative exposure to elevated cholesterol and blood pressure in development of atherosclerotic coronary artery disease in systemic lupus erythematosus: a prospective proof-of-concept cohort study. <i>Arthritis Research and Therapy</i> , 2011, 13, R156.	3.5	71
162	Defining Low Disease Activity in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017, 69, 997-1003.	3.4	71

#	ARTICLE	IF	CITATIONS
163	SLEDAI-2K for a 30-day window. <i>Lupus</i> , 2010, 19, 49-51.	1.6	70
164	Predictors of response to intra-articular steroid injection in psoriatic arthritis. <i>Rheumatology</i> , 2010, 49, 1367-1373.	1.9	70
165	The burden of carotid artery plaques is higher in patients with psoriatic arthritis compared with those with psoriasis alone. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 715-720.	0.9	70
166	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1530-1536.	0.9	70
167	Increased burden of inflammation over time is associated with the extent of atherosclerotic plaques in patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1830-1835.	0.9	70
168	Modified Framingham Risk Factor Score for Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2016, 43, 875-879.	2.0	70
169	Antinuclear Antibodyâ€“Negative Systemic Lupus Erythematosus in an International Inception Cohort. <i>Arthritis Care and Research</i> , 2019, 71, 893-902.	3.4	70
170	Association of the L1 gene cluster with susceptibility to ankylosing spondylitis: An analysis of three Canadian populations. <i>Arthritis and Rheumatism</i> , 2006, 54, 974-985.	6.7	69
171	Radiographic Progression of Patients With Psoriatic Arthritis Who Achieve Minimal Disease Activity in Response to Golimumab Therapy: Results Through 5 Years of a Randomized, Placeboâ€“Controlled Study. <i>Arthritis Care and Research</i> , 2016, 68, 267-274.	3.4	69
172	Brief Report: CXCL10 Is a Possible Biomarker for the Development of Psoriatic Arthritis Among Patients With Psoriasis. <i>Arthritis and Rheumatology</i> , 2016, 68, 2911-2916.	5.6	68
173	Epigenetics of psoriatic disease: A systematic review and critical appraisal. <i>Journal of Autoimmunity</i> , 2017, 78, 29-38.	6.5	68
174	Trends in the Prevalence and Incidence of Psoriasis and Psoriatic Arthritis in Ontario, Canada: A Populationâ€“Based Study. <i>Arthritis Care and Research</i> , 2019, 71, 1084-1091.	3.4	68
175	Psoriatic arthritis. <i>Dermatologic Therapy</i> , 2004, 17, 350-363.	1.7	67
176	Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review. <i>Journal of Rheumatology</i> , 2016, 43, 54-65.	2.0	67
177	Diagnosis and Management of Psoriatic Arthritis. <i>Drugs</i> , 2002, 62, 2447-2457.	10.9	66
178	Risk Factors for Development of Coronary Artery Disease in Women with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 2454-2461.	2.0	66
179	Is ASDAS better than BASDAI as a measure of disease activity in axial psoriatic arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2160-2164.	0.9	66
180	Hla-dr4 in giant cell arteritis: association with polymyalgia rheumatica syndrome. <i>Arthritis and Rheumatism</i> , 1987, 30, 1293-1297.	6.7	65

#	ARTICLE	IF	CITATIONS
181	Is There an Advantage Over SF-36 with a Quality of Life Measure That Is Specific to Systemic Lupus Erythematosus?. <i>Journal of Rheumatology</i> , 2011, 38, 1898-1905.	2.0	63
182	Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. <i>Lupus Science and Medicine</i> , 2014, 1, e000031.	2.7	63
183	Factors Explaining the Discrepancy Between Physician and Patient Global Assessment of Joint and Skin Disease Activity in Psoriatic Arthritis Patients. <i>Arthritis Care and Research</i> , 2015, 67, 264-272.	3.4	63
184	Clinical Aspects of the Spondyloarthropathies. <i>American Journal of the Medical Sciences</i> , 1998, 316, 234-238.	1.1	63
185	Early Psoriatic Arthritis. <i>Rheumatic Disease Clinics of North America</i> , 2012, 38, 373-386.	1.9	62
186	Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. <i>Journal of Rheumatology</i> , 2008, 35, 469-71.	2.0	62
187	The significance of thrombocytopenia in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1983, 26, 1181-1186.	6.7	60
188	Brief Report: Reduced Joint Counts Misclassify Patients With Oligoarticular Psoriatic Arthritis and Miss Significant Numbers of Patients With Active Disease. <i>Arthritis and Rheumatism</i> , 2013, 65, 1504-1509.	6.7	60
189	The clinical assessment of patients with psoriatic arthritis: results of a reliability study of the spondyloarthritis research consortium of Canada. <i>Journal of Rheumatology</i> , 2004, 31, 1126-31.	2.0	60
190	Responses to Adalimumab in Patients with Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-label Study. <i>Journal of Rheumatology</i> , 2010, 37, 1898-1906.	2.0	57
191	The association between sonographic enthesitis and radiographic damage in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2017, 19, 189.	3.5	57
192	International spondyloarthritis interobserver reliability exercise--the INSPIRE study: I. Assessment of spinal measures. <i>Journal of Rheumatology</i> , 2007, 34, 1733-9.	2.0	57
193	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. <i>Arthritis and Rheumatism</i> , 2000, 13, 406-408.	6.7	56
194	Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 649-655.	1.2	55
195	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1478-1487.	3.4	55
196	Long-term experience with apremilast in patients with psoriatic arthritis: 5-year results from a PALACE 1â€³3 pooled analysis. <i>Arthritis Research and Therapy</i> , 2019, 21, 118.	3.5	55
197	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 281-289.	5.6	55
198	Contributions of Observational Cohort Studies in Systemic Lupus Erythematosus: The University of Toronto Lupus Clinic Experience. <i>Rheumatic Disease Clinics of North America</i> , 2005, 31, 211-221.	1.9	54

#	ARTICLE	IF	CITATIONS
199	Disease course patterns in systemic lupus erythematosus. <i>Lupus</i> , 2019, 28, 114-122.	1.6	54
200	Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study. <i>Rheumatology and Therapy</i> , 2020, 7, 553-580.	2.3	54
201	Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies. <i>Lancet Rheumatology</i> , The, 2021, 3, e715-e723.	3.9	53
202	Incidence and prevalence of psoriatic arthritis in Denmark: a nationwide register linkage study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1591-1597.	0.9	52
203	Human leukocyte antigen alleles and susceptibility to psoriatic arthritis. <i>Human Immunology</i> , 2013, 74, 1333-1338.	2.4	51
204	Sensitivity and specificity of the CASPAR criteria for psoriatic arthritis in a family medicine clinic setting. <i>Journal of Rheumatology</i> , 2008, 35, 2069-70; author reply 2070.	2.0	51
205	Psoriatic arthritis. <i>Bailliere's Clinical Rheumatology</i> , 1995, 9, 319-329.	1.0	50
206	HLA is a candidate region for psoriatic arthritis. <i>Human Immunology</i> , 2003, 64, 887-889.	2.4	50
207	Tumour necrosis factor $\hat{\pm}$ blockers are more effective than methotrexate in the inhibition of radiographic joint damage progression among patients with psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1007-1011.	0.9	50
208	Validation of the Toronto Psoriatic Arthritis Screen Version 2 (ToPAS 2). <i>Journal of Rheumatology</i> , 2015, 42, 841-846.	2.0	50
209	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	3.4	50
210	HLA markers for susceptibility and expression in scleroderma. <i>Journal of Rheumatology</i> , 2005, 32, 1481-7.	2.0	50
211	Longitudinal study of the bidirectional association between pain and depressive symptoms in patients with psoriatic arthritis. <i>Arthritis Care and Research</i> , 2012, 64, 758-765.	3.4	49
212	Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. <i>Rheumatology</i> , 2014, 53, 233-239.	1.9	49
213	Evolution of Risk Factors for Atherosclerotic Cardiovascular Events in Systemic Lupus Erythematosus: A Longterm Prospective Study. <i>Journal of Rheumatology</i> , 2017, 44, 1841-1849.	2.0	49
214	Association of Tumor Necrosis Factor Inhibitor Treatment With Reduced Indices of Subclinical Atherosclerosis in Patients With Psoriatic Disease. <i>Arthritis and Rheumatology</i> , 2018, 70, 408-416.	5.6	49
215	Clinical and radiological changes during psoriatic arthritis disease progression. <i>Journal of Rheumatology</i> , 2003, 30, 1022-6.	2.0	49
216	Soluble Biomarkers Associated with Response to Treatment with Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 866-871.	2.0	48

#	ARTICLE	IF	CITATIONS
217	Axial involvement in psoriatic arthritis: An update for rheumatologists. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 880-887.	3.4	48
218	Impaired antigen-specific suppressor cell activity in patients with rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1980, 23, 1246-1250.	6.7	47
219	Current concepts in psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 2002, 14, 361-366.	4.3	46
220	Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. <i>RMD Open</i> , 2019, 5, e000808.	3.8	46
221	Ethnic variation in disease patterns and health outcomes in systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2006, 33, 1990-5.	2.0	46
222	Folate Pathway Enzyme Gene Polymorphisms and the Efficacy and Toxicity of Methotrexate in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1508-1512.	2.0	45
223	Minimal Disease Activity and Anti-Tumor Necrosis Factor Therapy in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2015, 67, 842-847.	3.4	45
224	Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study. <i>Journal of Rheumatology</i> , 2018, 45, 378-384.	2.0	45
225	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	2.0	45
226	Hyperuricemia in Psoriatic Arthritis. <i>Journal of Clinical Rheumatology</i> , 2000, 6, 6-9.	0.9	44
227	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. <i>RMD Open</i> , 2019, 5, e000806.	3.8	44
228	Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand?. <i>Lupus</i> , 2013, 22, 1243-1250.	1.6	43
229	Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 1426-1439.	2.0	43
230	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	2.0	43
231	The Phenotype of Axial Spondyloarthritis: Is It Dependent on HLA-B*27 Status?. <i>Arthritis Care and Research</i> , 2021, 73, 856-860.	3.4	43
232	Inflammation in an individual joint predicts damage to that joint in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 305-308.	0.9	42
233	2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part II: Specific Management Recommendations. <i>Journal of Rheumatology</i> , 2015, 42, 665-681.	2.0	42
234	Atherosclerosis in psoriatic disease: latest evidence and clinical implications. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2015, 7, 187-195.	2.7	42

#	ARTICLE	IF	CITATIONS
235	From Childhood to Adulthood: The Trajectory of Damage in Patients With Juvenile-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017, 69, 1627-1635.	3.4	42
236	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	2.0	42
237	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 370-378.	0.9	42
238	Do current arterial hypertension treatment guidelines apply to systemic lupus erythematosus patients? A critical appraisal. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 521-525.	3.4	41
239	Reappraisal of OMERACT 8 Draft Validation Criteria for a Soluble Biomarker Reflecting Structural Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis: The OMERACT 9 v2 Criteria. <i>Journal of Rheumatology</i> , 2009, 36, 1785-1791.	2.0	40
240	A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. <i>Arthritis and Rheumatology</i> , 2016, 68, 1932-1944.	5.6	40
241	Differential gene and protein expression of chemokines and cytokines in synovial fluid of patients with arthritis. <i>Arthritis Research and Therapy</i> , 2016, 18, 296.	3.5	40
242	Association of systemic lupus erythematosus (SLE) genetic susceptibility loci with lupus nephritis in childhood-onset and adult-onset SLE. <i>Rheumatology</i> , 2020, 59, 90-98.	1.9	40
243	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 356-362.	0.9	40
244	HLA antigens in north american patients with takayasu arteritis. <i>Arthritis and Rheumatism</i> , 1992, 35, 573-575.	6.7	39
245	2014 Update of the Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Treatment Recommendations for the Management of Spondyloarthritis. Part I: Principles of the Management of Spondyloarthritis in Canada. <i>Journal of Rheumatology</i> , 2015, 42, 654-664.	2.0	39
246	Prevalence and risk factors of low bone mineral density in psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 174-182.	3.4	39
247	The Risk of Developing Diabetes Mellitus in Patients with Psoriatic Arthritis: A Cohort Study. <i>Journal of Rheumatology</i> , 2017, 44, 286-291.	2.0	39
248	The Association Between Obesity and Clinical Features of Psoriatic Arthritis: A Case-control Study. <i>Journal of Rheumatology</i> , 2017, 44, 437-443.	2.0	39
249	Sleep Disturbance in Psoriatic Disease: Prevalence and Associated Factors. <i>Journal of Rheumatology</i> , 2017, 44, 1369-1374.	2.0	39
250	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. <i>Arthritis and Rheumatology</i> , 2020, 72, 67-77.	5.6	39
251	Clinically active serologically quiescent systemic lupus erythematosus. <i>Journal of Rheumatology</i> , 2003, 30, 1960-2.	2.0	39
252	Clinical Aspects of the Spondyloarthropathies. <i>American Journal of the Medical Sciences</i> , 1998, 316, 234-238.	1.1	38

#	ARTICLE	IF	CITATIONS
253	Interferon- β induces altered transitional B cell signaling and function in Systemic Lupus Erythematosus. <i>Journal of Autoimmunity</i> , 2015, 58, 100-110.	6.5	38
254	What have we learned about genetic susceptibility in psoriasis and psoriatic arthritis?. <i>Current Opinion in Rheumatology</i> , 2015, 27, 91-98.	4.3	38
255	Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 38.	3.5	38
256	Changes in Lipid Levels and Incidence of Cardiovascular Events Following Tofacitinib Treatment in Patients With Psoriatic Arthritis: A Pooled Analysis Across Phase 3 and Long-Term Extension Studies. <i>Arthritis Care and Research</i> , 2019, 71, 1387-1395.	3.4	38
257	Effects of ustekinumab on spondylitis-associated endpoints in TNFi-naïve active psoriatic arthritis patients with physician-reported spondylitis: pooled results from two phase 3, randomised, controlled trials. <i>RMD Open</i> , 2020, 6, e001149.	3.8	38
258	PSORIATIC ARTHRITIS: RECENT ADVANCES IN PATHOGENESIS AND TREATMENT. <i>Rheumatic Disease Clinics of North America</i> , 1992, 18, 247-256.	1.9	38
259	Differential human leucocyte allele association between psoriasis and psoriatic arthritis: a family-based association study. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1361-1365.	0.9	37
260	Psoriatic Arthritis: Phenotypic Variance and Nosology. <i>Current Rheumatology Reports</i> , 2013, 15, 316.	4.7	37
261	Psoriatic arthritis disease activity during pregnancy and the first-year postpartum. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 740-745.	3.4	37
262	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. <i>Rheumatology</i> , 2018, 57, 677-687.	1.9	37
263	Radiographic Progression According to Baseline C-reactive Protein Levels and Other Risk Factors in Psoriatic Arthritis Treated with Tofacitinib or Adalimumab. <i>Journal of Rheumatology</i> , 2019, 46, 1089-1096.	2.0	37
264	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
265	Outcome measures in psoriatic arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 2262-9.	2.0	37
266	Myocardial Perfusion Imaging in Assessing Risk of Coronary Events in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2009, 36, 288-294.	2.0	36
267	Gene Expression Differences between Psoriasis Patients with and without Inflammatory Arthritis. <i>Journal of Investigative Dermatology</i> , 2015, 135, 620-623.	0.7	36
268	Back pain in psoriatic arthritis: defining prevalence, characteristics and performance of inflammatory back pain criteria in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1573-1577.	0.9	36
269	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	2.0	36
270	Predictive Utility of Cardiovascular Risk Prediction Algorithms in Inflammatory Rheumatic Diseases: A Systematic Review. <i>Journal of Rheumatology</i> , 2020, 47, 928-938.	2.0	36

#	ARTICLE	IF	CITATIONS
271	Anti-dsDNA antibody testing by Farr and ELISA techniques is not equivalent. <i>Journal of Rheumatology</i> , 2006, 33, 1785-8.	2.0	36
272	Update on Biomarkers in Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2010, 12, 288-294.	4.7	35
273	Development of a Disease Severity and Responder Index for Psoriatic Arthritis (PsA) – Report of the OMERACT 10 PsA Special Interest Group. <i>Journal of Rheumatology</i> , 2011, 38, 1496-1501.	2.0	35
274	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. <i>RMD Open</i> , 2016, 2, e000217.	3.8	35
275	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
276	Development of Screening Tools to Identify Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2010, 12, 295-299.	4.7	34
277	Development of a Disease Activity and Responder Index for Psoriatic Arthritis – Report of the Psoriatic Arthritis Module at OMERACT 11. <i>Journal of Rheumatology</i> , 2014, 41, 782-791.	2.0	34
278	Enhanced Patient Involvement and the Need to Revise the Core Set – Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015, 42, 2198-2203.	2.0	34
279	Serum-based soluble markers differentiate psoriatic arthritis from osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 796-801.	0.9	34
280	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2020, 47, 72-81.	2.0	34
281	Effect of Psoriatic Arthritis According to the Affected Categories of the International Classification of Functioning, Disability and Health. <i>Journal of Rheumatology</i> , 2010, 37, 1885-1891.	2.0	33
282	Incidence of Uveitis in Secukinumab-treated Patients With Ankylosing Spondylitis: Pooled Data Analysis From Three Phase 3 Studies. <i>ACR Open Rheumatology</i> , 2020, 2, 294-299.	2.1	33
283	Inhibition of Mitogen Mediated Lymphocyte Blastogenesis by Adenosine. <i>Immunological Investigations</i> , 1975, 4, 419-427.	0.8	32
284	Longitudinal Analysis of Fatigue in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2010, 37, 1878-1884.	2.0	32
285	Serum kallikrein-8 correlates with skin activity, but not psoriatic arthritis, in patients with psoriatic disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 317-325.	2.3	32
286	Updated Guidelines for the Management of Axial Disease in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2014, 41, 2286-2289.	2.0	32
287	Informing Response Criteria for Psoriatic Arthritis (PsA). II: Further Considerations and a Proposal – The PsA Joint Activity Index. <i>Journal of Rheumatology</i> , 2010, 37, 2559-2565.	2.0	31
288	Diffuse Idiopathic Skeletal Hyperostosis in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2013, 40, 1367-1373.	2.0	31

#	ARTICLE	IF	CITATIONS
289	A novel lupus activity index accounting for glucocorticoids: SLEDAI-2K glucocorticoid index. <i>Rheumatology</i> , 2018, 57, 1370-1376.	1.9	31
290	Therapeutic benefit of apremilast on enthesitis and dactylitis in patients with psoriatic arthritis: a pooled analysis of the PALACE 1&2 studies. <i>RMD Open</i> , 2018, 4, e000669.	3.8	31
291	Clinical Remission and Low Disease Activity Outcomes Over 10 Years in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2019, 71, 822-828.	3.4	31
292	Antimalarial-induced Cardiomyopathy in Systemic Lupus Erythematosus: As Rare as Considered?. <i>Journal of Rheumatology</i> , 2019, 46, 391-396.	2.0	31
293	Fatigue numeric rating scale validity, discrimination and responder definition in patients with psoriatic arthritis. <i>RMD Open</i> , 2020, 6, e000928.	3.8	31
294	Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1.1-2.	0.9	31
295	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. <i>Lupus Science and Medicine</i> , 2021, 8, e000590.	2.7	31
296	The Long-Term Use of Azathioprine in Patients with Psoriatic Arthritis. <i>Journal of Clinical Rheumatology</i> , 2001, 7, 160-165.	0.9	30
297	Effectiveness of psoriatic arthritis therapies. <i>Seminars in Arthritis and Rheumatism</i> , 2003, 33, 29-37.	3.4	30
298	Seasonal variation in vitamin D levels in psoriatic arthritis patients from different latitudes and its association with clinical outcomes. <i>Arthritis Care and Research</i> , 2011, 63, 1440-1447.	3.4	30
299	The Incidence and Predictors of Infection in Psoriasis and Psoriatic Arthritis: Results from Longitudinal Observational Cohorts. <i>Journal of Rheumatology</i> , 2016, 43, 362-366.	2.0	30
300	Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110579.	2.7	30
301	Single photon emission computed tomography dual isotope myocardial perfusion imaging in women with systemic lupus erythematosus. II. Predictive factors for perfusion abnormalities. <i>Journal of Rheumatology</i> , 2003, 30, 288-91.	2.0	30
302	Time and predictors of response to tumour necrosis factor- α blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort. <i>Rheumatology</i> , 2010, 49, 1361-1366.	1.9	29
303	Cardiovascular Comorbidities in Psoriasis and Psoriatic Arthritis: Pathogenesis, Consequences for Patient Management, and Future Research Agenda: A Report from the GRAPPA 2009 Annual Meeting. <i>Journal of Rheumatology</i> , 2011, 38, 567-571.	2.0	29
304	Patient-reported Outcome in Psoriatic Arthritis: A Comparison of Web-based Versus Paper-completed Questionnaires. <i>Journal of Rheumatology</i> , 2011, 38, 2619-2624.	2.0	29
305	Recent advances in understanding and managing psoriatic arthritis. <i>F1000Research</i> , 2016, 5, 2670.	1.6	29
306	Hospitalizations in Patients with Systemic Lupus Erythematosus in an Academic Health Science Center. <i>Journal of Rheumatology</i> , 2017, 44, 1173-1178.	2.0	29

#	ARTICLE	IF	CITATIONS
307	Functional impairment measurement in psoriatic arthritis: Importance and challenges. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 436-448.	3.4	29
308	Assessing structural damage progression in psoriatic arthritis and its role as an outcome in research. <i>Arthritis Research and Therapy</i> , 2020, 22, 18.	3.5	29
309	Effectiveness and Safety of Etanercept in Patients with Psoriatic Arthritis in a Canadian Clinical Practice Setting: The REPARe Trial. <i>Journal of Rheumatology</i> , 2011, 38, 1355-1362.	2.0	28
310	Effect of Disease Activity on Organ Damage Progression in Systemic Lupus Erythematosus: University of Toronto Lupus Clinic Cohort. <i>Journal of Rheumatology</i> , 2021, 48, 67-73.	2.0	28
311	Bowel involvement in systemic lupus erythematosus: Crohn's disease or lupus vasculitis?. <i>Arthritis and Rheumatism</i> , 1985, 28, 466-470.	6.7	27
312	Psoriatic Arthritis from Wright's Era Until Today. <i>Journal of rheumatology Supplement, The</i> , 2009, 83, 4-8.	2.2	27
313	Anti-dsDNA and Antichromatin Antibody Isotypes in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2015, 42, 810-816.	2.0	27
314	Smoking Is the Most Significant Modifiable Lung Cancer Risk Factor in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 393-396.	2.0	27
315	Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). <i>Rheumatology</i> , 2018, 57, 1777-1788.	1.9	27
316	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. <i>Journal of Autoimmunity</i> , 2020, 106, 102340.	6.5	27
317	The baseline interferon signature predicts disease severity over the subsequent 5 years in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2021, 23, 29.	3.5	27
318	Informing Response Criteria for Psoriatic Arthritis. I: Discrimination Models Based on Data from 3 Anti-Tumor Necrosis Factor Randomized Studies. <i>Journal of Rheumatology</i> , 2010, 37, 1892-1897.	2.0	26
319	Composite Measures in Psoriatic Arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010, 37, 453-461.	2.0	26
320	Autoantibody response to adjuvant and nonadjuvant H1N1 vaccination in systemic lupus erythematosus. <i>Arthritis Care and Research</i> , 2011, 63, 1517-1520.	3.4	26
321	Psoriasis in systemic lupus erythematosus: a single-center experience. <i>Clinical Rheumatology</i> , 2017, 36, 879-884.	2.2	26
322	Characteristic and Outcome of Psoriatic Arthritis Patients with Hyperuricemia. <i>Journal of Rheumatology</i> , 2018, 45, 213-217.	2.0	26
323	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. <i>Arthritis and Rheumatology</i> , 2020, 72, 658-666.	5.6	26
324	Reliability of Radiographic Scoring Methods in Axial Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1417-1422.	3.4	25

#	ARTICLE	IF	CITATIONS
325	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1297-1307.	5.6	25
326	Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 612-617.	0.9	25
327	Adalimumab, etanercept and infliximab are equally effective treatments for patients with psoriatic arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 510-511.	3.2	24
328	Variability over time and correlates of cholesterol and blood pressure in systemic lupus erythematosus: a longitudinal cohort study. <i>Arthritis Research and Therapy</i> , 2010, 12, R125.	3.5	24
329	Development of Criteria to Distinguish Inflammatory from Noninflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1249-1251.	2.0	24
330	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 965-969.	2.0	24
331	Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial. <i>RMD Open</i> , 2017, 3, e000415.	3.8	24
332	Summarizing disease features over time: II. Variability measures of SLEDAI-2K. <i>Journal of Rheumatology</i> , 2007, 34, 336-40.	2.0	24
333	HLA-DRB1*04 alleles in psoriatic arthritis: comparison with rheumatoid arthritis and healthy controls. <i>Human Immunology</i> , 2001, 62, 1239-1244.	2.4	23
334	Recognizing psoriatic arthritis in the dermatology clinic. <i>Journal of the American Academy of Dermatology</i> , 2010, 63, 733-748.	1.2	23
335	Systemic lupus erythematosus: an update on current pharmacotherapy and future directions. <i>Expert Opinion on Biological Therapy</i> , 2013, 13, 723-737.	3.1	23
336	Epigenome-wide analysis of sperm cells identifies IL22 as a possible germ line risk locus for psoriatic arthritis. <i>PLoS ONE</i> , 2019, 14, e0212043.	2.5	23
337	How can we define low disease activity in systemic lupus erythematosus?. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 1035-1040.	3.4	23
338	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2020, 72, 1800-1808.	3.4	23
339	Mortality in psoriatic arthritis: Risk, causes of death, predictors for death. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 571-575.	3.4	23
340	The correlation between carotid artery atherosclerosis and clinical ischemic heart disease in lupus patients. <i>Lupus</i> , 2014, 23, 1142-1148.	1.6	22
341	Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients With Psoriatic Disease. <i>Arthritis and Rheumatology</i> , 2019, 71, 1651-1659.	5.6	22
342	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. <i>Arthritis Care and Research</i> , 2021, 73, 1231-1235.	3.4	22

#	ARTICLE	IF	CITATIONS
343	Depression and Anxiety Reduce the Probability of Achieving a State of Sustained Minimal Disease Activity in Patients With Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 1430-1434.	3.4	22
344	Gradual Glucocorticosteroid Withdrawal Is Safe in Clinically Quiescent Systemic Lupus Erythematosus. <i>ACR Open Rheumatology</i> , 2021, 3, 550-557.	2.1	22
345	Toward unraveling the mystery of psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 1993, 36, 881-884.	6.7	21
346	Variability and correlates of high sensitivity C-reactive protein in systemic lupus erythematosus. <i>Lupus</i> , 2009, 18, 966-973.	1.6	21
347	Recommendations for Frequency of Visits to Monitor Systemic Lupus Erythematosus in Asymptomatic Patients: Data from an Observational Cohort Study. <i>Journal of Rheumatology</i> , 2013, 40, 630-633.	2.0	21
348	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. <i>Arthritis Care and Research</i> , 2018, 70, 1294-1302.	3.4	21
349	Outcome of pregnancy in women with psoriatic arthritis compared to healthy controls. <i>Clinical Rheumatology</i> , 2019, 38, 895-902.	2.2	21
350	Trends in mortality and cause-specific mortality among patients with psoriasis and psoriatic arthritis in Ontario, Canada. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 1302-1309.	1.2	21
351	Significance of Clinical Evaluation of the Metacarpophalangeal Joint in Relation to Synovial/Bone Pathology in Rheumatoid and Psoriatic Arthritis Detected by Magnetic Resonance Imaging. <i>Journal of Rheumatology</i> , 2009, 36, 2751-2757.	2.0	20
352	Measuring participation in people with spondyloarthritis using the social role participation questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1765-1769.	0.9	20
353	Repair of Radiographic Joint Damage Following Treatment with Etanercept in Psoriatic Arthritis Is Demonstrable by 3 Radiographic Methods. <i>Journal of Rheumatology</i> , 2011, 38, 1066-1070.	2.0	20
354	More Consistent Antimalarial Intake in First 5 Years of Disease Is Associated with Better Prognosis in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2018, 45, 90-94.	2.0	20
355	Classification and Outcome Measures for Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 246.	2.6	20
356	New EULAR/ACR 2019 SLE Classification Criteria: defining ominousity in SLE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 767-774.	0.9	20
357	Relationship between spinal mobility and radiographic damage in ankylosing spondylitis and psoriatic spondylitis: a comparative analysis. <i>Journal of Rheumatology</i> , 2007, 34, 2463-5.	2.0	20
358	Isolated Hematuria and Sterile Pyuria May Indicate Systemic Lupus Erythematosus Activity. <i>Journal of Rheumatology</i> , 2015, 42, 437-440.	2.0	19
359	What Is Axial Psoriatic Arthritis?. <i>Journal of Rheumatology</i> , 2018, 45, 1611-1613.	2.0	19
360	Measurement properties of the minimal disease activity criteria for psoriatic arthritis. <i>RMD Open</i> , 2019, 5, e001002.	3.8	19

#	ARTICLE	IF	CITATIONS
361	Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. <i>RMD Open</i> , 2020, 6, e001217.	3.8	19
362	Relationship Between Genetic Risk and Age of Diagnosis in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021, 48, 852-858.	2.0	19
363	Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study. <i>Lancet Rheumatology</i> , The, 2021, 3, e270-e283.	3.9	19
364	Imaging in Psoriasis and Psoriatic Arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010, 37, 448-452.	2.0	18
365	Biomarkers in Psoriasis and Psoriatic Arthritis: GRAPPA 2008. <i>Journal of Rheumatology</i> , 2010, 37, 462-467.	2.0	18
366	Physician scores vs patient self-report of joint and skin manifestations in psoriatic arthritis. <i>Rheumatology</i> , 2013, 52, 705-711.	1.9	18
367	The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1227-1229.	2.0	18
368	Utility of untimed single urine protein/creatinine ratio as a substitute for 24-h proteinuria for assessment of proteinuria in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 296.	3.5	18
369	Lack of Interferon and Proinflammatory Cyto/chemokines in Serologically Active Clinically Quiescent Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2015, 42, 2318-2326.	2.0	18
370	Benchmarking Care in Psoriatic Arthritis – The QUANTUM Report: A Report from the GRAPPA 2016 Annual Meeting. <i>Journal of Rheumatology</i> , 2017, 44, 674-678.	2.0	18
371	Treating Psoriasis and Psoriatic Arthritis: Position Paper on Applying the Treat-to-target Concept to Canadian Daily Practice. <i>Journal of Rheumatology</i> , 2017, 44, 519-534.	2.0	18
372	Association of variably expressed KIR3dl1 alleles with psoriatic disease. <i>Clinical Rheumatology</i> , 2017, 36, 2261-2266.	2.2	18
373	From Childhood to Adulthood: Disease Activity Trajectories in Childhood-Onset Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 750-757.	3.4	18
374	Abnormal Cardiac Biomarkers in Patients with Systemic Lupus Erythematosus and No Prior Heart Disease: A Consequence of Antimalarials?. <i>Journal of Rheumatology</i> , 2019, 46, 64-69.	2.0	18
375	The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 638-643.	3.4	18
376	Treating Psoriatic Arthritis to Target: Defining the Psoriatic Arthritis Disease Activity Score That Reflects a State of Minimal Disease Activity. <i>Journal of Rheumatology</i> , 2020, 47, 362-368.	2.0	18
377	Liver Abnormalities in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2020, 47, 847-853.	2.0	18
378	Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. <i>Lupus Science and Medicine</i> , 2022, 9, e000651.	2.7	18

#	ARTICLE	IF	CITATIONS
379	A variant of the <i>IL4</i> 150V single nucleotide polymorphism is associated with erosive joint disease in psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 2207-2208.	6.7	17
380	Design and rationale of the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA). <i>RMD Open</i> , 2018, 4, e000606.	3.8	17
381	Identifying and Characterizing Psoriasis and Psoriatic Arthritis Patients in Ontario Administrative Data: A Population-based Study From 1991 to 2015. <i>Journal of Rheumatology</i> , 2020, 47, 1644-1651.	2.0	17
382	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. <i>Arthritis and Rheumatology</i> , 2020, 72, 1734-1740.	5.6	17
383	Axial Disease in Psoriatic arthritis: The presence and progression of unilateral grade 2 sacroiliitis in a psoriatic arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 464-468.	3.4	17
384	The Spondyloarthritis Research Consortium of Canada Registry for Spondyloarthritis. <i>Journal of Rheumatology</i> , 2011, 38, 1343-1348.	2.0	16
385	Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2016, 43, 1718-1723.	2.0	16
386	Methods for analyzing observational longitudinal prognosis studies for rheumatic diseases: a review & worked example using a clinic-based cohort of juvenile dermatomyositis patients. <i>Pediatric Rheumatology</i> , 2017, 15, 18.	2.1	16
387	GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e23-e23.	0.9	16
388	Secukinumab Immunogenicity over 52 Weeks in Patients with Psoriatic Arthritis and Ankylosing Spondylitis. <i>Journal of Rheumatology</i> , 2020, 47, 539-547.	2.0	16
389	Axial Psoriatic Arthritis. <i>Current Rheumatology Reports</i> , 2021, 23, 35.	4.7	16
390	Psoriatic Arthritis. <i>BioDrugs</i> , 1998, 9, 271-278.	4.6	15
391	Traditional and Newer Therapeutic Options for Psoriatic Arthritis. <i>Drugs</i> , 2005, 65, 1223-1238.	10.9	15
392	Review of Clinical Registries of Psoriatic Arthritis: Lessons Learned? Value for the Future?. <i>Current Rheumatology Reports</i> , 2011, 13, 346-352.	4.7	15
393	Gender-related differences in patients with psoriatic arthritis. <i>International Journal of Clinical Rheumatology</i> , 2012, 7, 641-649.	0.3	15
394	Further Evidence Supporting a Parent-of-Origin Effect in Psoriatic Disease. <i>Arthritis Care and Research</i> , 2015, 67, 1586-1590.	3.4	15
395	Thrombovascular Events Affect Quality of Life in Patients with Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2011, 38, 1017-1019.	2.0	14
396	Relationship between cardiac symptoms, myocardial perfusion defects and coronary angiography findings in systemic lupus erythematosus. <i>Lupus</i> , 2011, 20, 299-304.	1.6	14

#	ARTICLE	IF	CITATIONS
397	High-sensitivity C-reactive protein as a marker of cardiovascular risk in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2012, 64, 3052-3053.	6.7	14
398	Predictors for clinical outcome in psoriatic arthritis – what have we learned from cohort studies?. <i>Expert Review of Clinical Immunology</i> , 2014, 10, 763-770.	3.0	14
399	Disease Outcomes in Glucocorticosteroid-Naive Patients With Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2017, 69, 252-256.	3.4	14
400	Sensitivity and Specificity of Radiographic Scoring Instruments for Detecting Change in Axial Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2017, 69, 1700-1705.	3.4	14
401	Magnetic Resonance Imaging in Psoriatic Arthritis. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 243-245.	0.9	14
402	The Association Between HLA Genetic Susceptibility Markers and Sonographic Enthesitis in Psoriatic Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 756-762.	5.6	14
403	The Relationship Between Physical Examination and Ultrasonography of Large Entheses of the Achilles Tendon and Patellar Tendon Origin. <i>Journal of Rheumatology</i> , 2020, 47, 1026-1030.	2.0	14
404	Declining levels of serum chemokine (CXCL10) ligand 10 over time are associated with new onset of psoriatic arthritis in patients with psoriasis: a new biomarker?*. <i>British Journal of Dermatology</i> , 2020, 183, 920-927.	1.5	14
405	Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. <i>Rheumatology</i> , 2021, 60, 4737-4747.	1.9	14
406	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	2.0	14
407	Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. <i>Rheumatology and Therapy</i> , 2021, 8, 1789-1808.	2.3	14
408	Kidney Biopsy in SLE. I. A Clinical-Morphologic Evaluation. <i>QJM - Monthly Journal of the Association of Physicians</i> , 1989, .	0.5	13
409	Damage in lupus patients – what have we learned so far?. <i>Lupus</i> , 2013, 22, 1225-1231.	1.6	13
410	Patient Participation in Psoriasis and Psoriatic Arthritis Outcome Research: A Report from the GRAPPA 2013 Annual Meeting. <i>Journal of Rheumatology</i> , 2014, 41, 1206-1211.	2.0	13
411	Addressing comorbidities in psoriatic disease. <i>Rheumatology International</i> , 2018, 38, 219-227.	3.0	13
412	Patterns of peripheral joint involvement in psoriatic arthritis – Symmetric, ray and/or row?. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 430-435.	3.4	13
413	The relationship between patient acceptable symptom state and disease activity in patients with psoriatic arthritis. <i>Rheumatology</i> , 2020, 59, 69-76.	1.9	13
414	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. <i>Arthritis Care and Research</i> , 2021, 73, 1789-1795.	3.4	13

#	ARTICLE	IF	CITATIONS
415	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 1137-1147.	1.9	13
416	Barriers to medication adherence and degree of nonadherence in a systemic lupus erythematosus (SLE) outpatient population. <i>Rheumatology International</i> , 2021, 41, 1457-1464.	3.0	13
417	Identifying a Response for the Systemic Lupus Erythematosus Disease Activity 2000 Glucocorticoid Index. <i>Arthritis Care and Research</i> , 2021, 73, 1243-1249.	3.4	13
418	Atherosclerotic Vascular Events in Systemic Lupus Erythematosus: An Evolving Story. <i>Journal of Rheumatology</i> , 2020, 47, 66-71.	2.0	13
419	Association of killer cell immunoglobulin-like receptor genotypes with vascular arterial events and anticardiolipin antibodies in patients with lupus. <i>Lupus</i> , 2008, 17, 793-798.	1.6	12
420	Editorial: What Is Peripheral Spondyloarthritis?. <i>Arthritis and Rheumatology</i> , 2015, 67, 865-868.	5.6	12
421	Cost-effectiveness analysis of secukinumab for the treatment of active psoriatic arthritis: a Canadian perspective. <i>Journal of Medical Economics</i> , 2018, 21, 163-173.	2.1	12
422	Practice Variations in the Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus in Canada. <i>Journal of Rheumatology</i> , 2018, 45, 1440-1447.	2.0	12
423	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1010-1012.	0.9	12
424	2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2019, 4, 31-58.	0.7	12
425	Long-term Safety and Tolerability of Apremilast Versus Placebo in Psoriatic Arthritis: A Pooled Safety Analysis of Three Phase III, Randomized, Controlled Trials. <i>ACR Open Rheumatology</i> , 2020, 2, 459-470.	2.1	12
426	Health Care Utilization for Musculoskeletal Issues During the Prediagnosis Period in Psoriatic Arthritis: A Population-Based Study. <i>Arthritis Care and Research</i> , 2021, 73, 680-686.	3.4	12
427	Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial. <i>Journal of Rheumatology</i> , 2022, 49, 885-893.	2.0	12
428	Mixed leukocyte reaction in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1976, 19, 532-538.	6.7	11
429	Prologue: 2009 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , 2011, 38, 522-525.	2.0	11
430	Prologue: 2011 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , 2012, 39, 2181-2183.	2.0	11
431	Psoriatic Arthritis in Canadian Clinical Practice: The PsA Assessment in Rheumatology. <i>Journal of Rheumatology</i> , 2012, 39, 1850-1853.	2.0	11
432	The Association of HLA-class I Genes and the Extent of Atherosclerotic Plaques in Patients with Psoriatic Disease. <i>Journal of Rheumatology</i> , 2016, 43, 1844-1851.	2.0	11

#	ARTICLE	IF	CITATIONS
433	Composite Measures of Disease Activity in Psoriatic Arthritis: Comparative Instrument Performance Based on the Efficacy of Guselkumab in an Interventional Phase II Trial. <i>Arthritis Care and Research</i> , 2020, 72, 1579-1588.	3.4	11
434	Targeted metabolomic profiling and prediction of cardiovascular events: a prospective study of patients with psoriatic arthritis and psoriasis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1429-1435.	0.9	11
435	The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 547-552.	3.4	11
436	Prologue: 2012 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , 2013, 40, 1407-1409.	2.0	10
437	Prevalence and associated factors of resting electrocardiogram abnormalities among systemic lupus erythematosus patients without cardiovascular disease. <i>Arthritis Research and Therapy</i> , 2017, 19, 31.	3.5	10
438	Physician's Global Assessment in Psoriatic Arthritis: A Multicenter GRAPPA Study. <i>Journal of Rheumatology</i> , 2018, 45, 1256-1262.	2.0	10
439	Effect of Secukinumab on the Different GRAPPA-OMERACT Core Domains in Psoriatic Arthritis: A Pooled Analysis of 2049 Patients. <i>Journal of Rheumatology</i> , 2020, 47, 854-864.	2.0	10
440	Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis. <i>Current Therapeutic Research</i> , 2020, 93, 100601.	1.2	10
441	Malignancy in psoriatic disease: Results from prospective longitudinal cohorts. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 144-149.	3.4	10
442	Evolving concepts in systemic lupus erythematosus damage assessment. <i>Nature Reviews Rheumatology</i> , 2021, 17, 307-308.	8.0	10
443	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	2.0	10
444	The SLICC inception cohort for atherosclerosis. <i>Current Rheumatology Reports</i> , 2008, 10, 281-285.	4.7	9
445	Does the change in season affect disease activity in patients with psoriatic arthritis?. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1370-1373.	0.9	9
446	A Hot Spot for Systemic Lupus Erythematosus, but Not for Psoriatic Arthritis, Identified by Spatial Analysis Suggests an Interaction Between Ethnicity and Place of Residence. <i>Arthritis and Rheumatism</i> , 2013, 65, 1579-1585.	6.7	9
447	Vaccination and auto-immune rheumatic diseases. <i>Current Opinion in Rheumatology</i> , 2013, 25, 164-170.	4.3	9
448	Prologue: 2013 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , 2014, 41, 1194-1196.	2.0	9
449	Comparison of systemic lupus erythematosus (SLE) patients managed early after diagnosis in specialty versus community care clinics. <i>Clinical Rheumatology</i> , 2017, 36, 1773-1778.	2.2	9
450	Should methotrexate remain the first-line drug for psoriasis?. <i>Lancet</i> , The, 2017, 389, 482-483.	13.7	9

#	ARTICLE	IF	CITATIONS
451	Using Acute-phase Reactants to Inform the Development of Instruments for the Updated Psoriatic Arthritis Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 46, 266-273.	2.0	9
452	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€¦). <i>Arthritis Care and Research</i> , 2020, , .	3.4	9
453	Incidence of and Risk Factors for Heart Failure in Patients With Psoriatic Disease: A Cohort Study. <i>Arthritis Care and Research</i> , 2022, 74, 1244-1253.	3.4	9
454	Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinib. <i>Arthritis Research and Therapy</i> , 2021, 23, 94.	3.5	9
455	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1143-1150.	0.9	9
456	Effect of bimekizumab on symptoms and impact of disease in patients with psoriatic arthritis over 3 years: results from BE ACTIVE. <i>Rheumatology</i> , 2023, 62, 617-628.	1.9	9
457	Can we identify psoriatic arthritis early?. <i>Current Rheumatology Reports</i> , 2008, 10, 419-421.	4.7	8
458	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. <i>Rheumatology</i> , 2019, 58, 1259-1267.	1.9	8
459	Late onset psoriatic arthritis in a longitudinal cohort: Disease presentation, activity over time and prognosis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 834-839.	3.4	8
460	Advanced Chronic Kidney Disease in Lupus Nephritis: Is Dialysis Inevitable?. <i>Journal of Rheumatology</i> , 2020, 47, 1366-1373.	2.0	8
461	Immunoglobulin levels in systemic lupus erythematosus: A narrative review. <i>Lupus</i> , 2021, 30, 867-875.	1.6	8
462	Updates on Axial Psoriatic Arthritis From the 2020 GRAPPA Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201672.	2.0	8
463	Clinical and genetic registries in psoriatic disease. <i>Journal of Rheumatology</i> , 2008, 35, 1458-63.	2.0	8
464	Th17 gene expression in psoriatic arthritis synovial fluid and peripheral blood compared to osteoarthritis and cutaneous psoriasis. <i>Clinical and Experimental Rheumatology</i> , 2018, 36, 486-489.	0.8	8
465	Atlantoaxial subluxation in a patient with psoriatic arthritis. <i>Arthritis and Rheumatism</i> , 1989, 32, 1338-1339.	6.7	7
466	Psoriatic arthritis. <i>Current Opinion in Rheumatology</i> , 1990, 2, 577-581.	4.3	7
467	Current and investigational treatment of psoriatic arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 139-150.	4.1	7
468	Early-Onset Obesity and Risk for Psoriatic ArthritisOBESITY AND RISK FOR PSORIATIC ARTHRITIS. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 787.	7.4	7

#	ARTICLE	IF	CITATIONS
469	Outcome measures in systemic lupus erythematosus. <i>Indian Journal of Rheumatology</i> , 2013, 8, S46-S53.	0.4	7
470	SLEDAI-2K Does Not Conceal Worsening in a Particular System When There Is Overall Improvement. <i>Journal of Rheumatology</i> , 2015, 42, 1401-1405.	2.0	7
471	Clinical and Demographic Characteristics of Erosion-free and Erosion-present Status in Psoriatic Arthritis in a Cohort Study. <i>Journal of Rheumatology</i> , 2016, 43, 1057-1062.	2.0	7
472	The utility of lupus serology in predicting outcomes of renal transplantation in lupus patients: Systematic literature review and analysis of the Toronto lupus cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 46, 791-797.	3.4	7
473	FRI0509â€¦Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from opal balance, an open-label, long-term extension study. , 2017, , .		7
474	Evidence for Psoriatic Arthritis Impact of Disease (PsAID12) as Core Instrument to Measure Health-Related Quality of Life in Psoriatic Arthritis: A Systematic Review of Psychometric Properties. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 2020, 5, 12-22.	0.7	7
475	Remission in psoriatic arthritis: Definition and predictors. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1494-1499.	3.4	7
476	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. <i>Arthritis and Rheumatology</i> , 2021, 73, 2293-2302.	5.6	7
477	GRAPPA 2018 Project Report. <i>Journal of Rheumatology</i> , 2019, 95, 54-57.	2.0	7
478	GRAPPA 2019 Project Report. <i>Journal of Rheumatology</i> , 2020, 96, 53-57.	2.0	7
479	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2023, 75, 998-1006.	3.4	7
480	AB0160â€¦Epigenetic Studies in Maternally versus Paternally Transmitted Psoriatic Disease. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 856.1-856.	0.9	6
481	Review of the Psoriatic Arthritis Working Group at OMERACT 12: A Report from the GRAPPA 2014 Annual Meeting. <i>Journal of Rheumatology</i> , 2015, 42, 1048-1051.	2.0	6
482	Letâ€™s Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 970-973.	2.0	6
483	Integrative Approach to Reveal Cell Type Specificity and Gene Candidates for Psoriatic Arthritis Outside the MHC. <i>Frontiers in Genetics</i> , 2019, 10, 304.	2.3	6
484	Treatmentâ€™s Target With Apremilast in Psoriatic Arthritis: The Probability of Achieving Targets and Comprehensive Control of Disease Manifestations. <i>Arthritis Care and Research</i> , 2020, 72, 814-821.	3.4	6
485	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1158-1181.	3.4	6
486	Propensity Score Methods in Rare Disease: A Demonstration Using Observational Data in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2021, 48, 321-325.	2.0	6

#	ARTICLE	IF	CITATIONS
487	Factors Associated With Rapid Progression to Endstage Kidney Disease in Lupus Nephritis. <i>Journal of Rheumatology</i> , 2021, 48, 228-231.	2.0	6
488	Medium Versus High Initial Prednisone Dose for Remission Induction in Lupus Nephritis: A Propensity Score–Matched Analysis. <i>Arthritis Care and Research</i> , 2022, 74, 1451-1458.	3.4	6
489	Secukinumab Efficacy on Psoriatic Arthritis GRAPPA-OMERACT Core Domains in Patients with or Without Prior Tumor Necrosis Factor Inhibitor Use: Pooled Analysis of Four Phase 3 Studies. <i>Rheumatology and Therapy</i> , 2021, 8, 1223-1240.	2.3	6
490	Targeted therapy for psoriatic arthritis. <i>Nature Reviews Rheumatology</i> , 2009, 5, 241-242.	8.0	5
491	Clinical Measures, Metrics, and Indices. , 2013, , 563-581.		5
492	A novel role for the psoriatic arthritis impact of disease (PsAID) questionnaire. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 241-245.	3.4	5
493	Prevalence and Factors Associated With Osteoporosis and Bone Mineral Density Testing in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2022, 74, 1006-1012.	3.4	5
494	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 58-66.	2.0	5
495	Oligoarticular vs Polyarticular Psoriatic Arthritis: A Longitudinal Study Showing Similar Characteristics. <i>Journal of Rheumatology</i> , 2021, 48, 1824-1829.	2.0	5
496	The Benefits and Challenges of Setting Up a Longitudinal Psoriatic Arthritis Database. <i>Journal of Rheumatology</i> , 2018, 94, 26-29.	2.0	5
497	Best-practice Indicators in Psoriatic Disease Care. <i>Journal of Rheumatology</i> , 2019, 95, 38-45.	2.0	5
498	Association of Cardiac Biomarkers With Cardiovascular Outcomes in Patients With Psoriatic Arthritis and Psoriasis: A Longitudinal Cohort Study. <i>Arthritis and Rheumatology</i> , 2022, 74, 1184-1192.	5.6	5
499	Future Trends in Research in Psoriatic Arthritis. <i>Journal of rheumatology Supplement</i> , The, 2012, 89, 106-110.	2.2	4
500	OP0042â€¦Do We Know How and When to Stop Immunosuppressants in Lupus Patients?. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 76-76.	0.9	4
501	DEVELOPING AN IPAD® APPLICATION FOR DATA COLLECTION IN A RHEUMATOLOGY RESEARCH CLINIC. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 99-102.	0.5	4
502	On Modelling Minimal Disease Activity. <i>Arthritis Care and Research</i> , 2016, 68, 388-393.	3.4	4
503	SAT0293â€¦Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the third interim analysis of opal balance, an open-label, long-term extension study. , 2018, , .		4
504	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1117-1124.	3.4	4

#	ARTICLE	IF	CITATIONS
505	Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo. <i>Arthritis Research and Therapy</i> , 2022, 24, 40.	3.5	4
506	Longitudinal cohort studies. <i>Journal of rheumatology Supplement, The</i> , 2005, 72, 30-2.	2.2	4
507	Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2022, 49, 694-699.	2.0	4
508	On Defining Musculoskeletal Inflammation: A Report from the GRAPPA 2011 Annual Meeting. <i>Journal of Rheumatology</i> , 2012, 39, 2214-2215.	2.0	3
509	GRAPPA 2015 Research and Education Project Reports. <i>Journal of Rheumatology</i> , 2016, 43, 979-985.	2.0	3
510	OPO202â€¦Efficacy and safety of tofacitinib, an oral janus kinase inhibitor, in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: opal beyond, a randomised, double-blind, placebo-controlled, phase 3 trial. , 2017, , .		3
511	FRIO498â€¦Outcomes associated with achievement of various treatment targets in patients with psoriatic arthritis receiving adalimumab. , 2017, , .		3
512	Comparison Between INSPIRE and Domjan method for measuring lumbar lateral flexion in patients of psoriatic arthritis (PsA) and correlation with radiographic damage. <i>Clinical Rheumatology</i> , 2019, 38, 1063-1066.	2.2	3
513	Systematic literature review of non-topical treatments for early, untreated (systemic therapy naïve) psoriatic disease: a GRAPPA initiative. <i>Rheumatology Advances in Practice</i> , 2020, 4, rkaa032.	0.7	3
514	Response to placebo in non-renal, non-neuropsychiatric systemic lupus erythematosus: a systematic review and pooled analysis. <i>Rheumatology</i> , 2021, 60, 73-80.	1.9	3
515	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1547-1551.	2.0	3
516	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. <i>Lupus</i> , 2021, 30, 096120332110142.	1.6	3
517	Factors associated with refractory renal disease in patients with systemic lupus erythematosus: The role of patient nonadherence. <i>Arthritis and Rheumatism</i> , 2000, 13, 406-408.	6.7	3
518	The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial. <i>Lancet Rheumatology, The</i> , 2022, 4, e208-e219.	3.9	3
519	Reporting of mortality in a psoriatic arthritis clinic is primarily a function of the number of clinic contacts and not disease severity. <i>Journal of Rheumatology</i> , 2005, 32, 2364-7.	2.0	3
520	Correspondence on â€œNo efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related â€œphysician-reported spondylitisâ€™?â€™. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e187-e187.	0.9	3
521	Spondyloarthropathies. <i>Current Opinion in Rheumatology</i> , 2004, 16, 329-330.	4.3	2
522	A novel, disease-specific quality-of-life instrument for patients with SLE. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 132-133.	3.2	2

#	ARTICLE	IF	CITATIONS
523	Pharmacoeconomics of adalimumab for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. Expert Review of Pharmacoeconomics and Outcomes Research, 2008, 8, 111-125.	1.4	2
524	Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2008. Journal of Rheumatology, 2010, 37, 446-447.	2.0	2
525	Biomarkers for Comorbidities in Psoriasis: A Report from the Grappa 2011 Annual Meeting. Journal of Rheumatology, 2012, 39, 2193-2195.	2.0	2
526	Immunoglobulin G Subclass Analysis in Psoriatic Arthritis. Journal of Rheumatology, 2014, 41, 2421-2424.	2.0	2
527	Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2014 Annual Meeting. Journal of Rheumatology, 2015, 42, 1041-1043.	2.0	2
528	AB0822...Therapeutic Response in Adalimumab-Treated Patients with Psoriatic Arthritis in Relation to Weight. Annals of the Rheumatic Diseases, 2015, 74, 1175.1-1175.	0.9	2
529	Is it time for treat to target in psoriatic arthritis?. Lancet, The, 2015, 386, 2450-2452.	13.7	2
530	Toward Treating to Target in Psoriatic Arthritis. Journal of rheumatology Supplement, The, 2015, 93, 14-16.	2.2	2
531	Presidential Round Table: A Report from the GRAPPA Annual Meeting. Journal of Rheumatology, 2016, 43, 986-989.	2.0	2
532	S1D:5...Sle disease activity index glucocorticosteroid index (sle dai-2kg) identifies more responders than sle dai-2k. , 2018, , .		2
533	Case Report of Refractory Psoriatic Arthritis Achieving Remission Using <i>Nigella sativa</i> (Black) Tj ETQq1 1 0.784314 rgBT /Overlo	2.0	2
534	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 2021, , jrheum.201679.	2.0	2
535	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. Seminars in Arthritis and Rheumatism, 2021, 51, 367-386.	3.4	2
536	Health-related quality of life of patients with psoriatic arthritis: A comparison with patients with rheumatoid arthritis. Arthritis and Rheumatism, 2001, 45, 151-158.	6.7	2
537	SAT0270...Low incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis. , 2018, , .		2
538	Exploring cannabis use and perspectives among psoriatic disease patients. Clinical Rheumatology, 2022, 41, 1431-1437.	2.2	2
539	Assessment of disease activity in lupus. Transfusion Science, 1992, 13, 129-134.	0.6	1
540	Assessing lupus. Arthritis and Rheumatism, 1998, 41, 2276-2276.	6.7	1

#	ARTICLE	IF	CITATIONS
541	Management of Psoriatic Arthritis. , 2010, , 55-69.		1
542	SAT0404â€¦Spot Urine Protein/Creatinine Ratio is Useful in Screening for Proteinuria but Should Not Substitute 24 hours Urine Collection Sample to Quantify Proteinuria in Lupus. Annals of the Rheumatic Diseases, 2015, 74, 805.2-806.	0.9	1
543	Historical Perspectives on Psoriatic Arthritis. , 2016, , 3-6.		1
544	FRI0522â€¦The association between occupational-related mechanical stress and radiographic damage in psoriatic arthritis. , 2017, , .		1
545	Oral treatment options for AS and PsA: DMARDs and small-molecule inhibitors. Best Practice and Research in Clinical Rheumatology, 2018, 32, 415-426.	3.3	1
546	FRI0450â€¦PROBABILITY OF ACHIEVING LOW DISEASE ACTIVITY OR REMISSION IN SUBJECTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH APREMILAST. , 2019, , .		1
547	Response to: â€œCan biomarkers differentiate psoriatic arthritis from osteoarthritis?â€™ by Tian <i>et al</i>. Annals of the Rheumatic Diseases, 2020, 79, e113-e113.	0.9	1
548	Canadian Rheumatologists' Perspectives on Moderate Psoriatic Arthritis and Oligoarticular Psoriatic Arthritis. Journal of Rheumatology, 2021, 48, jrheum.201195.	2.0	1
549	Current and investigational treatment of psoriatic arthritis. Expert Opinion on Investigational Drugs, 2004, 13, 139-150.	4.1	1
550	Assessment of the Toronto Psoriatic Arthritis Screen 2 as a Screening Tool for Psoriasis. Journal of Cutaneous Medicine and Surgery, 2022, 26, 237-242.	1.2	1
551	GRAPPA 2007: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis. Journal of Rheumatology, 2008, 35, 1420-2.	2.0	1
552	Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group. Journal of Rheumatology, 2022, , jrheum.211322.	2.0	1
553	Articular and Extra-Articular Benefits in ACR20 Non-responders at Week 104 Treated With Apremilast: Pooled Analysis of Three Randomized Controlled Trials. Rheumatology and Therapy, 2021, 8, 1677-1691.	2.3	1
554	Effectiveness of Disease Modifying Anti-Rheumatic Drugs for Enthesitis in a Prospective Longitudinal Psoriatic Arthritis Cohort. Journal of Rheumatology, 0, , jrheum.211231.	2.0	1
555	Psoriatic arthropathy. Current Opinion in Orthopaedics, 1995, 6, 4-7.	0.3	0
556	Spondyloarthropathies. Current Opinion in Rheumatology, 2005, 17, 393-394.	4.3	0
557	Clinical Features of Psoriatic Arthritis. , 2007, , 11-18.		0
558	BIOLOGIC THERAPY OF PSORIATIC ARTHRITIS. Reumatismo, 2011, 59, .	0.9	0

#	ARTICLE	IF	CITATIONS
559	Dr. Cauli, <i>et al</i> reply: Table 1.. Journal of Rheumatology, 2012, 39, 654-654.	2.0	0
560	Spondyloarthritis. , 2012, , 367-379.		0
561	Outcome Measures in Psoriatic Disease. Current Dermatology Reports, 2013, 2, 164-171.	2.1	0
562	OP0095â€¦Customized CNV microarray identified UGT2B17 as a novel susceptibility gene associated with familial ankylosing spondylitis. Annals of the Rheumatic Diseases, 2013, 71, 85.1-85.	0.9	0
563	FR10165â€¦The Molecular Convergence of Non-Hla Ankylosing Spondylitis Risk Genes with Autoimmune Diseases. Annals of the Rheumatic Diseases, 2014, 73, 441.3-442.	0.9	0
564	GRAPPA Historical Perspective. , 2016, , 7-14.		0
565	AB0794â€¦Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis: results from two phase 3 studies. , 2017, , .		0
566	Reply. Arthritis Care and Research, 2017, 69, 1934-1934.	3.4	0
567	AB0743â€¦Low rates of major adverse cardiac events, malignancies, and serious infections in patients with psoriasis and psoriatic arthritis treated with apremilast for 156 weeks: pooled analysis from the esteem and palace 1-3 phase 3 trials. , 2017, , .		0
568	SAT0462â€¦Secukinumab provides sustained pasdas related low disease activity in psoriatic arthritis: 2 year results from the future 2 study. , 2017, , .		0
569	SAT0448â€¦Apremilast treatment and long-term (up to 156 weeks) improvements in dactylitis and enthesitis in patients with psoriatic arthritis: analysis of a large database of the phase iii clinical development program. , 2017, , .		0
570	THU0299â€¦An integrated analysis of changes in lipid levels and incidence of cardiovascular events following tofacitinib treatment in patients with psoriatic arthritis across phase 3 and long-term extension studies. , 2018, , .		0
571	SAT0336â€¦Measurement properties of the minimal disease activity criteria for psoriatic arthritis. , 2018, , .		0
572	THU0300â€¦Network meta-analysis of tofacitinib vs bdmards or apremilast for the treatment of tnf inhibitor-naïve patients with psoriatic arthritis. , 2018, , .		0
573	CS-07â€¦Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
574	CS-36â€¦Recommendations for the assessment of systemic lupus erythematosus in canada. , 2018, , .		0
575	166â€¦Long-term (156-week) improvements in dactylitis and enthesitis with apremilast inpsoriatic arthritis subjects: analysis of a large, pooled PALACE 1-3 database. Rheumatology, 2018, 57, .	1.9	0
576	Dr. Tselios, et al, reply. Journal of Rheumatology, 2019, 46, 1422.2-1422.	2.0	0

#	ARTICLE	IF	CITATIONS
577	260â€fLow incidence of both new-onset and flares of uveitis in secukinumab-treated patients with ankylosing spondylitis: clinical trial and post-marketing safety analysis. <i>Rheumatology</i> , 2019, 58, .	1.9	0
578	263â€fSecukinumab, a fully human anti-interleukin-17A monoclonal antibody, exhibits low immunogenicity in patients with psoriatic arthritis and ankylosing spondylitis during a 52week treatment period. <i>Rheumatology</i> , 2019, 58, .	1.9	0
579	THU0031â€f...FILGOTINIB TREATMENT PROVIDES RAPID AND SUSTAINED REDUCTION OF INFLAMMATORY BIOMARKERS IN MODERATE TO SEVERE PSORIATIC ARTHRITIS (PSA) PATIENTS. , 2019, , .		0
580	FRI0429â€f...NON TOPICAL PHARMACOLOGICAL TREATMENT OF EARLY, UNTREATED (DMARD-NAÃ-VE, SYSTEMIC) Tj ETQq0 0 0 rgBT /O		
581	OP0109â€f...EFFICACY OF FILGOTINIB VS PLACEBO IN ACTIVE PSORIATIC ARTHRITIS: PATIENT-LEVEL DATA FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY. , 2019, , .		0
582	SAT0373â€f...EFFECT OF FILGOTINIB ON PATIENT-REPORTED OUTCOMES IN ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM EQUATOR, A RANDOMIZED, PHASE 2 STUDY. , 2019, , .		0
583	SAT0369â€f...SECUKINUMAB IMPROVES GRAPPA-OMERACT CORE DOMAINS OF PSORIATIC ARTHRITIS REGARDLESS OF PREVIOUS EXPOSURE TO A TNF INHIBITOR. , 2019, , .		0
584	Disease development and outcome. , 2021, , 37-45.		0
585	Prologue: 2020 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). <i>Journal of Rheumatology</i> , 2021, , jrheum.201666.	2.0	0
586	Response to: Correspondence on â€œNew EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLEâ€by Whittall Garcia et al. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-221014.	0.9	0
587	Spondyloarthritis: Psoriatic Arthritis. , 2014, , 1110-1115.		0
588	Management of psoriatic arthritis. , 2015, , 1008-1013.		0
589	THU0294â€f...5-year efficacy and safety of apremilast treatment in subjects with psoriatic arthritis: pooled analysis of the palace studies. , 2018, , .		0
590	AB0946â€f...Improvements in work productivity with up to 104 weeks of apremilast monotherapy: results from a phase 3b, randomised, controlled study in biologic-naÃve subjects with active psoriatic arthritis. , 2018, , .		0
591	AB0921â€f...Impact of baseline demographics, disease activity and concomitant medication on american college of rheumatology 20 response rate and health assessment questionnaire-disability index score with tofacitinib in active psoriatic arthritis: a pooled subgroup analysis of 2 phase 3 studies. , 2018, , .		0
592	1501â€f...Genetics of age at systemic lupus erythematosus diagnosis. , 2021, , .		0
593	1124â€f...Economic evaluation of neuropsychiatric (NP) lupus in an international inception cohort using a multistate model approach. , 2021, , .		0
594	1107â€f...Economic evaluation of hydroxychloroquine use in an international inception cohort. , 2021, , .		0

#	ARTICLE	IF	CITATIONS
595	1704â€¦Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
596	The incidence and risk factors for venous thromboembolic events in patients with psoriasis and psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2022, 53, 151950.	3.4	0
597	Prologue: 2021 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Journal of Rheumatology, 2022, , jrheum.211317.	2.0	0
598	P258â€¦Secukinumab Improves Physical Function and Inhibits Structural Damage in Psoriatic Arthritis PsA Patients With Sustained Remission or Low Disease Activity: Results From a Phase 3 Study. Rheumatology, 2022, 61, .	1.9	0
599	P266â€¦Secukinumab provides clinical improvements in patients with active oligoarticular psoriatic arthritis: results from a pooled analysis of five phase 3 studies. Rheumatology, 2022, 61, .	1.9	0